Matthew Kurian, Assistant Professor of Medicine at the University of Kentucky College of Medicine and Physician at St. Elizabeth Healthcare, shared a post by Andre Esteva, Co-Founder and CEO of Artera, adding:
“AI in Breast Cancer Is Hitting a New Gear at SABCS25
Artificial intelligence isn’t the future anymore – it’s finally becoming clinically actionable. This year, ArteraAI is showcasing how multimodal AI from routine H&E slides can deliver fast, scalable, and accessible prognostic + predictive insights for HR+ early breast cancer. Huge for community oncology and for equity.
PD11-01 (#1251)
MMAI model for 10-yr distant metastasis (12,000+ pts)
- Clear risk stratification
- 68% low-risk w 95% 10-yr DM-FS
- Large, international validation
PS3-04-08 (#1410)
Independent ABCSG-8 validation (endocrine-therapy-only)
- Low / intermediate / high-risk groups: 95% / 89% / 77%
- Strong performance across grade, nodes, histology, Ki-67
- Fast, non-destructive, cost-conscious alternative to genomic testing
RF3-03 (#3685)
NSABP B-20: Predicting chemo benefit
- In node-negative HR+ pts ≥50:
- High-risk → 52% reduction in 10-yr DM with chemo
- Low-risk → no chemo benefit
- How will this stack up against oncotype and mammaprint?
Why this matters
AI + digital pathology is enabling accessible precision oncology. Prognostic AND predictive power – without extra tissue, long wait times (shorter than oncotype or mammaprint), or high cost. This is how we deliver academic-level decision support in every clinic. Oncotype and mammaprint both have their limitations in certain node negative or select node 1-3 positive groups.
Exciting momentum at SABCS2025!! Look forward to great discussion regarding this and how people will view a 3rd assay entering the arena.”
Quoting Andre Esteva‘s post:
“ArteraAI is now a validated multi-cancer company.
The ArteraAI Breast Test has remarkable evidence supporting its clinical utility. It’ll be presented at the San Antonio Breast Cancer Symposium next month – the top conference in breast cancer. We’ve shown across numerous phase III clinical trials that it is prognostic of patient outcomes and can predict therapeutic benefit (i.e. which therapy is right for you?)
Three presentations including an oral session.
Remarkable work Artera team. Read more.”
More posts featuring Matthew Kurian on OncoDaily.